A prospective national precision medicine trial evaluating the feasibility of blood-based molecular profiling in patients with Cancer of Unknown Primary (CUP-COMP)

Le résumé fourni par la source

BACKGROUND: Cancer of Unknown Primary (CUP) is an aggressive malignancy with poor patient outcomes. For most patients, the primary site remains elusive, limiting therapeutic options to non-specific chemotherapy. The CUP-COMP study (NCT04750109) assessed the feasibility of integrating molecular profiling with a National Molecular Tumour Board (MTB) into the treatment pathway of patients with CUP. METHODS: Patients with histologically confirmed CUP were recruited from seven UK sites. Blood- and/or tissue-based molecular profiling was performed with results interpreted via an MTB identifying potentially actionable alterations (PAA). Retrospective tissue and blood alteration analysis assessed concordance and utility. RESULTS: 113/117 patients recruited between June 2021 and February 2023 completed 12 months of follow-up. Of 115 patients with successful molecular profiling, blood-based profiling was more successful (93%) than tissue-based (61%). The MTB identified PAAs in 63% (73/115), with 26% (31/117) treated using a precision medicine (PM) approach. Primary tumours were subsequently confirmed/suspected in 41 patients. Median overall survival (OS) was 9.5 months. Detecting a PAA in blood was impacted by tumour fraction (33% of patients had a tumour fraction <1%). DISCUSSION: CUP-COMP demonstrates liquid biopsies are highly feasible in CUP. While tissue profiling remains preferable, blood-based profiling offers a timely viable alternative to tissue, especially in selected patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.